Bibliography for: "Canon U.S.A. and EFI Launch Fiery-Driven Server for Canon Customers in High-Quality, Color Demanding Professional Print Environments"

"Canon U.S.A. and EFI Launch Fiery-Driven Server for Canon Customers in High-Quality, Color Demanding Professional Print Environments". Business Wire. FindArticles.com. 22 Dec, 2009. http://findarticles.com/p/articles/mi_m0EIN/is_2008_Oct_26/ai_n30935434/

Business Wire

View more issues:

Articles in Oct 26, 2008 issue of Business Wire

• 2008 Ad
• 2008 Ad
• Pfizer to Present Data on New Approaches to Pain and Inflammation Treatment at ACR Meeting
• Kamada: Pivotal Phase III Data Confirms Efficacy and Safety of Intravenous Alpha-1 Antitrypsin
• Konica Minolta and EFI Launch Fiery-Driven Servers for New bizhub PRO Line-Up
• 2008 Ad
• Canon Ushers in a New Era of Black-and-White Printing with the Introduction of the imagePRESS 1135/1125/1110
• Canon U.S.A.'s imagePRESS C7000VP Utilized in Developing Award-Winning, Digital Output
• Canon U.S.A. Introduces The imagePRESS C1+ Featuring Clear Toner
• Canon U.S.A. Adds Vivid Toner Clear and Exact Black Toner to Its Family of Genuine Canon Supplies
• EFI Fiery Drives New Ricoh Production Printer; Increases Customers' ROI with Top Speed, Quality and VDP Features
• Canon U.S.A. Launches New Customer Productivity Program for Its Color imagePRESS Digital Presses
• Two New Paper Offerings Join Canon's Media Line-up for Its Office Product Systems
• Canon U.S.A. Unveils the imagePRESS Essential Business Builder Program Web Site
• OfficeMax to Roll Out Canon's imagePROGRAF iPF 6000S and iPF 8000S Large Format Printers
• Canon U.S.A. and EFI Launch Fiery-Driven Server for Canon Customers in High-Quality, Color Demanding Professional Print Environments
• Fox Reality Channel Presents Decision 2008 - The "Real" Election! Which Wanna-Be Do You Wanna See?
• 2008 Ad
• New Phase III Study in Previously Untreated HIV Patients Showed Merck's ISENTRESS® Reduced HIV Viral Load to Undetectable Levels, Comparable to Efavirenz, When Taken in Combination with Other Medicines
• Middlesex University Confers Honorary Doctorate on H.E. Sultan Bin Sulayem
• VaxInnate's Universal Flu Vaccine Candidate Shown Safe and Immunogenic in Phase I Clinical Study
• Targanta Presents Efficacy and Safety Data for Oritavancin for the Treatment of Gram-Positive Complicated Skin and Skin Structure Infections
• Targanta Therapeutics Presents Data on Mechanisms That Underly Oritavancin's Bactericidal Activity
• Array BioPharma's Oral p38 Inhibitor Demonstrates Significant Analgesic Benefit and Systemic Anti-Inflammatory Activity
• Progenics Reports Positive Interim Phase 2 Results for Two Dosage Forms of Novel HIV Therapy PRO 140
• Pfizer's Novel HIV/AIDS Treatment Selzentry™ Demonstrates Increased Efficacy Rate In Treatment-Naive HIV Patients
• Panacos Presents Phase 2b Bevirimat Data at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
• 96-Week Data From CASTLE Study Continue to Show Similar Efficacy Between Once-Daily REYATAZ® /Ritonavir and Twice-Daily Lopinavir/Ritonavir In Previously Untreated HIV-1 Infected Adult Patients
• Webcast Alert: Smith Micro Q3 2008 Earnings Conference Call Webcast
• Incyte's JAK Inhibitor Demonstrates Rapid and Marked Clinical Improvement in Rheumatoid Arthritis Patients